Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma

被引:9
作者
Kiong, Kimberley L. [1 ,4 ]
Bell, Diana [2 ]
Yao, Christopher M. K. L. [1 ]
Ferrarotto, Renata [3 ]
Lewis, Carol M. [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[4] Singapore Gen Hosp, Dept Otorhinolaryngol Head & Neck Surg, Singapore, Singapore
关键词
Pathology; Chemotherapy; Chemotherapy Head and Neck cancer; Squamous cell cancer; LOCALLY ADVANCED HEAD; LONG-TERM SURVIVAL; INDUCTION CHEMOTHERAPY; PROGNOSTIC-FACTORS; CANCER; SURGERY; CISPLATIN; TUMOR; CHEMORADIOTHERAPY; COMBINATION;
D O I
10.1016/j.oraloncology.2021.105520
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Complete pathological response after neoadjuvant chemotherapy (NAC) in head and neck squamous cell carcinomas (HNSCC) is a good prognostic factor. Multifocal regression post-NAC in breast cancer has proven to impact locoregional control (LRC) but has not been evaluated in HNSCC. We evaluate the impact of multifocal regression and major pathologic response (MPR) on survival indices in HNSCC. Materials and Methods: Retrospective review of HNSCC patients receiving NAC followed by surgery with curative intent between March 2016 to March 2019 at MD Anderson Cancer Center. Tumor focality (uni- or multifocal), pathologic response and other pathologic data were collected. MPR was defined as <= 10% residual tumor. Overall survival (OS) and LRC were analyzed and multivariate Cox regression analysis was performed. Results: 101 patients were analyzed, with 18.8% pathologic complete response, 18.8% with 1-10% viable tumor and 60.4% with > 10% viable tumor. 61 (60.4%) had unifocal disease while 19 (18.8%) had multifocal disease. Tumor focality was significantly associated with LRC but not OS, where the 3-year LRC was 82%, 69% and 52% (p = 0.015) for no viable tumor, unifocal disease and multifocal disease respectively. On multivariate analysis, multifocal disease (HR 10.43; 95 %CI 1.24-87.5) and extranodal extension (HR 4.4; 95 %CI 1.60-12.07) continued to be significant independent predictors of LRC. MPR group displayed significantly better 3-year OS (75% vs 51%, p = 0.041) and 3-year LRC (80% vs 62%, p = 0.011) than those with > 10% viable tumor. Conclusion: Multifocal regression and less than MPR after NAC in HNSCC predicts for locoregional recurrence and should be routinely reported.
引用
收藏
页数:8
相关论文
共 40 条
[1]   Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].
Alberro, J. A. ;
Ballester, B. ;
Deulofeu, P. ;
Fabregas, R. ;
Fraile, M. ;
Gubern, J. M. ;
Janer, J. ;
Moral, A. ;
de Pablo, J. L. ;
Penalva, G. ;
Puig, P. ;
Ramos, M. ;
Rojo, R. ;
Santesteban, P. ;
Serra, C. ;
Sola, M. ;
Solarnau, L. ;
Solsona, J. ;
Veloso, E. ;
Vidal, S. ;
Abe, O. ;
Abe, R. ;
Enomoto, K. ;
Kikuchi, K. ;
Koyama, H. ;
Masuda, H. ;
Nomura, Y. ;
Ohashi, Y. ;
Sakai, K. ;
Sugimachi, K. ;
Toi, M. ;
Tominaga, T. ;
Uchino, J. ;
Yoshida, M. ;
Coles, C. E. ;
Haybittle, J. L. ;
Moebus, V. ;
Leonard, C. F. ;
Calais, G. ;
Garaud, P. ;
Collett, V. ;
Davies, C. ;
Delmestri, A. ;
Sayer, J. ;
Harvey, V. J. ;
Holdaway, I. M. ;
Kay, R. G. ;
Mason, B. H. ;
Forbe, J. F. ;
Franci, P. A. .
LANCET ONCOLOGY, 2018, 19 (01) :27-39
[2]  
ALKOURAINY K, 1987, CANCER-AM CANCER SOC, V59, P233, DOI 10.1002/1097-0142(19870115)59:2<233::AID-CNCR2820590210>3.0.CO
[3]  
2-X
[4]   Defining risk levels in locally advanced head and neck cancers:: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501) [J].
Bernier, J ;
Cooper, JS ;
Pajak, TF ;
van Glabbeke, M ;
Bourhis, J ;
Forastiere, A ;
Ozsahin, EM ;
Jacobs, JR ;
Jassem, J ;
Ang, KK ;
Lefèbvre, JL .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (10) :843-850
[5]   THE EFFECT OF CHEMOTHERAPY IN RELATION TO PATHOHISTOLOGICAL TUMOR GRADING IN HEAD AND NECK-CANCER [J].
BOHEIM, K ;
SPOENDLIN, H .
ARCHIVES OF OTO-RHINO-LARYNGOLOGY-ARCHIV FUR OHREN-NASEN-UND KEHLKOPFHEILKUNDE, 1983, 238 (03) :197-204
[6]   Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience [J].
Brockstein, B ;
Haraf, DJ ;
Rademaker, AW ;
Kies, MS ;
Stenson, KM ;
Rosen, F ;
Mittal, BB ;
Pelzer, H ;
Fung, BB ;
Witt, ME ;
Wenig, B ;
Portugal, L ;
Weichselbaum, RW ;
Vokes, EE .
ANNALS OF ONCOLOGY, 2004, 15 (08) :1179-1186
[7]   Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience [J].
Chen, AM ;
Meric-Bernstam, F ;
Hunt, KK ;
Thames, HD ;
Oswald, MJ ;
Outlaw, ED ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Ross, MI ;
Singletary, SE ;
Ames, FC ;
Feig, BW ;
Sahin, AA ;
Perkins, GH ;
Schechter, NR ;
Hortobagyi, GN ;
Buchholz, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2303-2312
[8]   Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer [J].
Chitose, Shun-ichi ;
Chijiwa, Hideki ;
Maeda, Akiteru ;
Umeno, Hirohito ;
Nakashima, Tadashi ;
Kiyokawa, Kensuke ;
Hayabuchi, Naofumi ;
Fujita, Hiromasa .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2012, 269 (11) :2391-2399
[9]   PROGNOSTIC FACTORS FOR CHEMOTHERAPY RESPONSE AND SURVIVAL USING COMBINATION CHEMOTHERAPY AS INITIAL TREATMENT OF ADVANCED HEAD AND NECK SQUAMOUS-CELL CANCER [J].
COGNETTI, F ;
PINNARO, P ;
RUGGERI, EM ;
CARLINI, P ;
PERRINO, A ;
IMPIOMBATO, FA ;
CALABRESI, F ;
CHILELLI, MG ;
GIANNARELLI, D .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) :829-837
[10]  
CRISSMAN JD, 1984, CANCER-AM CANCER SOC, V54, P2995, DOI 10.1002/1097-0142(19841215)54:12<2995::AID-CNCR2820541230>3.0.CO